Content available at: https://www.ipinnovative.com/open-access-journals

Current Trends in Pharmacy and Pharmaceutical Chemistry

Journal homepage: https://www.ctppc.org/

Review Article

Recent advances in treatment of breast cancers

A.G. Nerkar[1,2,3,*]

[1] *Founder and Director, Ateos Foundation of Science Education and Research, Pune, Maharashtra, India*
[2] *Founder and Director, Carolene Therapeutics, Pvt. Ltd., Aurangabad, Maharashtra, India*
[3] *Editor in Chief, Current Trends in Pharmacy and Pharmaceutical Chemistry (ctppc.org)*

ARTICLE INFO

Article history:
Received 02-02-2022
Accepted 20-03-2022
Available online 19-05-2022

Keywords:
Breast cancer
Inhibitors of cyclin-dependent kinases 4 and 6
Hormone receptor
Human epidermal growth factor receptor 2
Poly (ADP-ribose) polymerase inhibitor

ABSTRACT

Growth factors receptors and hormones play an important role several cell minor cell types.
With advent of advancement in Breast cancer (BC) treatment and therapies ther of there has been major advancement in this area after this discovery. The combined sciences of cellular biology and therapeutic fields have made the breast cancer a seized cure area for discoveries of new therapies and its design including the heterogeneity. This article reviews the numerous prospective innovative therapies for targeting major cell subtypes of BC cells, as well as the present therapeutic regimens. In the personalised BC drug, speedy scientific advancement of poly inhibitors (ADP-ribose) polymerase, cyclin-dependent kinases four and six, phosphatidylinositol 3-kinase / protein kinase b / mammalian target rapamycin pathway, histone deacetylation, multi-concentrated in tyrosine kinases, as well as antibodies. The Triple negative breast cancer (TNBC) has been the most challenging area for design of therapies and for drug discovery. For TNBC, as such there is no approved treatment and it is most dangerous type of BC. The article also discusses the TNBC heterogeneity and TNBC molecular subtyping. It could also help find medications to treat this terrible disease. The cell proliferation and propagation inhibitors for treatment-resistant strains also puts the invention of targets for small molecules of BC in concern.

1. Introduction

Breast cancer (BC) is the well-known cause of death in women worldwide and TNBC the resistant type of BC has been fatal and challenging area for the discoveries of the drug. The classification of BC can be made in four primary types which is based on tests on numerous indicators, such as the existence of hormone receptors (HRS), higher levels of epidermal growth factor receptor 2 (her2) proteins, and/or replicas of her2 genes. [1]

Molecular cell types: (i) light a (HR + / HER2-); (ii) HER2 +; (iii) luminal b (HR + / HER2 +); and (iv) Triple poverty (TNBC; HR / HER2; in addition to the basal type fragmentation). Each of these subtypes are unique. Each subtype is also characterized by a unique set of risk, therapeutic responses, disease progress, and common metastatic sites. Luminal BC is characterized the HR [estrogenic receptor (ER) and progesterone receptor (PR)] and further subcategorized into a and b types. Luminal (HR + / HER2) has a slower growth rate and is less competitively smaller. Hormonal therapies have a high level of sensitivity in them. The Elevated ki67 (growth marker) or HER2 exposure determines the Luminal b subgroup. (HR + / HER2 +) is classified similarly in terms of assessment of luminal b is frequently lower than that of luminal-a. The Anti-her2 drugs can be used to manage Her2 + BC, which has overexpression or promotes her2 / erbb2 dependence. Because basal-like BC lacks HR and her2,

* *Corresponding author*.
E-mail address: dragnerkar@gmail.com (A. G. Nerkar).

https://doi.org/10.18231/j.ctppc.2022.013

it is sometimes known as triple-negative breast cancer (TNBC). The majority of patients with BC (84%) have HR + infections, with 71% having HR + / HER (luminal a) and 12% having HR + / HER2 + infections (luminal b). Only 5% of persons with BC have both her2 and HR. TNBC accounts for the remaining 12% of those affected. [2–4]

2. Current and Novel Therapies for different subtypes of BC

2.1. Luminal BC (HR+ BC)

2.1.1. Current treatment regimens

The most (60–80 percent) of BC cases in globalised nations are luminal BC, and it is an incredible hormone receptor (HR +), and this percentage is expanding in premenopausal girls. Endocrine therapy, which involves eliminating hormonal impacts or diminishing levels of hormones, is the core of management in HR + BC. Nowadays, the treatments to be used are: (i) tamoxifen, a prodrug that prevents estrogenic absorption via the ER; (ii) aromatase inhibitors (letrozole, anastrozole, and exemestane), which restrict the transformation of androgens to estrogens as an outcome of oestrogen decline; (iii) luteinizing hormone conjugates (goserelin and leuprolide), which inhibit uterine hormone generation; and (iv) fulvestrant (selected ER lowering), which is appropriate for BC patients who have not adhered to earlier hormone replacement therapy.

Until there is a requirement for quick response or indications of scientific resistance, when chemical remedy may be necessary, successful delivery of endocrine therapies is suggested. Because endocrine pills act in a unique way, they are frequently combined to have a greater anti-cancer effect. However, there have been reports of mixed results. Patients with advanced BC who have not had endocrine therapy and those with endocrine-resistant malignancies are thought to benefit considerably from combined endocrine therapy. [5]

2.1.2. Novel therapies

Metastatic HR + BC may increase resistance to traditional hormone therapy, which has turned to genetic manipulation within the ER and/or control of the formation of differential expression of new agents focused at reversing hormone treatments resistance choices. (Table 1).

2.2. Cyclin-dependent kinases 4 and six (CDK4/6 inhibitors)

CDK4/ 6 inhibitors (palbociclib, ribociclib, and abemaciclib) are among the newer medicines that have gotten a lot of interest. Despite its reverse interaction with cyclin d1, CDK4 / 6 affects cell cycle progress. Elevated cyclin d1 and CDK4 levels were seen in 29 and 14 percent of individuals with HR + HER2 BC, respectively. Importantly, even after treated with a blend of hormone therapy and a CDK4 / 6 inhibitor, the plants continued to rely on CDK4 / 6-cyclin d1. Cdk4 / 6 inhibitors impede G1-S binding by preventing the phosphorylation of retinoblastoma protein, efficiently controlling e2f-reaction genes. They also made the transcription issue fork head container protein m1 dephosphorylate to limit cell growth. Palbociclib and ribociclib have been approved by the FDA for use as first-line chemotherapy for HR + / HER2 superior BC when combined with an aromatase inhibitor. When compared to letrozole alone, they were proven to enhance central PFS by 20 percent post 10 months and PFS costs by 20 percent post 18 months, respectively. Abemaciclib, on the other hand, is still under evaluation under category iii (nct02246621). In HR + / HER2 advanced BC, in conjunction with fulvestrant as a second-line treatment. When compared to fulvestrant alone, palbociclib and abemaciclib have been demonstrated to increase central PFS by 5 months and 7 months, respectively. Ribociclib is now being studied in phase three (nct02422615). Despite the fact that all three cdk4/6 inhibitors work in the same way, abemaciclib had a better monotherapy response and reduced extremely low neutropenia, possibly due to its stronger cdk4 inhibition. [6]

2.3. Inhibitors targeting PI3K/ protein kinase b (AKT) / mammalian target of rapamycin (mTOR pathway)

Hormone resistance is thought to be caused by the opposing activation of the pi3k-AKT-MTOR signalling pathway. Over 70% of BC was spent using this manner. One of the most frequently changed and/or amplified genes is p110 (pik3ca), which encodes the pi3k catalytic subunit. To reverse hormone resistance, researchers used a combination of medications that targeted both HR techniques and PI3K/AKT/MTOR. [7]

2.3.1. PI3K pathways

As a second-line treatment for HR + / HER superior BC, a total of pi3k inhibitors and aromatase inhibitors were employed. Despite the fact that buparlisib (a pan-elegance PI3K inhibitor) has been proven to improve PFS, particularly in persons with PIK3CA mutations, buparlisib, pictillisib, pilaralisib, and voxtalisib (also a mTOR inhibitor) had no side effects. Excessive toxicity provides an excellent clinical ascending benefit. The extremely selective and toxic-precise pi3k inhibitors (alpeisib and taselisib), which are ongoing in phase iii trials (nct02437318 and nct02340221), have shown promise efficacy, particularly in BC patients with pik3ca mutations. [8]

Pictillisib and taselisib were demonstrated to enhance antitumor efficacy in hr+/her2 early bc patients when given as a neoadjuvant chemotherapy in combination with letrozole or anastrozole. Segment ii research is looking into buparlisb and alpelisib (NCT01923168). [9]

Table 1: Novel drugs for treating different molecular subtypes of breast cancer (BC).

Drug (alternative names)	Mode of action	Targeted population	Monotherapy or combination therapy	Latest stage of clinical development
I. For treating HR+ BC				
Ibrance	Oral small-molecule inhibitor of cyclindependent kinase CDK4 and CDK6	Advanced stage, HER2−	Combination therapy with letrozole	Approved by US FDA (February 2015)
		Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase III
Kisqali	Oral small-molecule inhibitor of CDK4 and CDK6	Advanced stage, HER2−	Combination therapy with letrozole	Approved by US FDA (March 2017)
		Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase III (ongoing
(LY2835219	Oral small-molecule inhibitor of CDK4 and CDK6	Advanced stage, HER2−	Combination therapy with letrozole	Phase III (ongoing)
		Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase III
(BKM120)	Oral small-molecule inhibitor of panclass	Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase III
	I phosphatidylinositol 3-kinase (PI3K)	Early stage, HER2−	Combination therapy with letrozole	Phase II (ongoing)
GDC-0941	Oral small-molecule inhibitor of panclass	Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase II
	I PI3K	Early stage, HER2−	Combination therapy with anaestrozole	Phase I/II (will not be further pursued
SAR245409	Oral small-molecule inhibitor of panclass	Advanced stage, pretreated, HER2−	Combination therapy with letrozole	Phase I/II (will not be further pursued)
	I PI3K and mammalian target of rapamycin (mTOR)			
BYL719	Oral small-molecule inhibitor of α-specific class	Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase III (ongoing)
	I PI3K	Early stage, HER2−	Combination therapy with letrozole	Phase II (ongoing)
GDC-0032	Oral small-molecule inhibitor of α-specific class I PI3K	Advanced stage, pretreated, HER2−	Combination therapy with fulvestrant	Phase II (ongoing)
Afintor	Oral small-molecule inhibitor of mTOR	Advanced stage, pretreated	Combination therapy with exemestane	Approved by US FDA (July 2012
Torisel	Oral small-molecule inhibitor of mTOR	Advanced stage	Combination therapy with letrozole	Phase III
		Advanced stage, pretreated	Monotherapy	Phase II (will not be further pursued)
Entinostat	Histone deacetylase (HDAC) inhibitor	Advanced stage, pretreated	Combination therapy with exemestane	Phase III (ongoing)
Vorinostat	HDAC inhibitor	Advanced stage, pretreated	Combination therapy with tamoxifen	Phase II
II. For treating HER2+ BC				
BKM120	Oral small-molecule inhibitor of panclass	Advanced stage, pretreated	Combination therapy with lapatinib	Phase Ib
				Phase II
	I PI3K	Advanced stage, pretreated	Combination therapy with trastuzumab and paclitaxel	
SAR245408	Oral small-molecule inhibitor of panclass	Advanced stage, pretreated	Combination therapy with trastuzumab/ trastuzumab and paclitaxel	Phase I/II
	I PI3K			
MK-2206	Oral small-molecule inhibitor of protein kinase B	Advanced stage, pretreated	Combination therapy with trastuzumab	Phase I

Table 1 Cont....

Afintor	Oral small-molecule inhibitor of mTOR	Advanced stage, pretreated	Combination therapy with trastuzumab and vinorelbine	Phase III
MK-8669	Oral small-molecule inhibitor of mTOR	Advanced stage, pretreated	Combination therapy with trastuzumab	Phase IIb
Sirolimus	Oral small-molecule inhibitor of mTOR	Advanced stage, pretreated	Combination therapy with trastuzumab	Phase II
HKI-272	Irreversible binder of HER1, HER2, and HER4	Early stage, pretreated	Monotherapy	Phase III
AMG 888, U3-1287	Anti-HER3 monoclonal antibody	Advanced stage	Combination therapy with trastuzumab and paclitaxel	Phase Ib
MGAH22	Anti-HER2 monoclonal antibody	Advanced stage	Monotherapy	Phase I
SCH66336	Farnesyl transferase inhibitor	Advanced stage	Combination therapy with trastuzumab and paclitaxel	Phase I
E75	Therapeutic peptide vaccine	Early stage	Combination therapy with trastuzumab	Phase II (ongoing)
dHER2	Therapeutic peptide vaccine	Early stage Advanced stage Advanced stage, pretreated	Monotherapy Monotherapy Combination therapy with lapatinib	Phase I Phase I/II Phase I
III. For treating triple negative breast cancer				
Lynparza	Oral PARP inhibitor	Advanced stage, HER2−, gBRCA+	Monotherapy	Phase III
BMN 673	Oral PARP inhibitor	Advanced stage, HER2−, gBRCA+	Monotherapy	Phase III (ongoing)
ABT-888	Oral PARP inhibitor	Advanced stage, HER2−, gBRCA+	Combination therapy with carboplatin and paclitaxel	Phase III (ongoing)
Zejula	Oral PARP inhibitor	Advanced stage, HER2−, gBRCA+	Monotherapy Combination therapy with pembrolizumab	Phase III (ongoing)
Rubraca	Oral PARP inhibitor	Advanced stage, HER2−, gBRCA+	Monotherapy Combination therapy with cisplatin	Phase I/II (ongoing)
Glembatumumab vedotin	Antibody-drug conjugate	Advanced stage, pretreated, gpNMB+	Monotherapy	Phase II (ongoing)
Casodex	Androgen-receptor inhibitor	Advanced stage, AR+, HR−	Monotherapy	Phase II
Keytruda	Anti-PD-1 monoclonal antibody	Advanced stage	Monotherapy	Phase II (ongoing)

2.3.2. MTOR Inhibitors

After failure of treatment with letrozole or anastrozole, Everolimus was approved by the USFDA for HR + advanced BC in combination with exemestane. Temisirolimus, on the other hand, failed to show any clinical benefits whether used as a first-line treatment in combination with letrozole or as a second-line treatment in advanced HR + BC as a single agent. [10]

2.3.3. Histone Deacetylase (HDAC Inhibitors)

Hormonal resistance in ER + patients is also attributable to the loss of histone deacetylation of ER expression. HDAC inhibitors, which promote Er and aromatase exposure while inhibiting partial signalling pathways, can help to reverse this. Each entinostat and vorinostat displayed improved cytotoxic concentrations when combination with exemestane and tamoxifen as a second chemotherapy in increased HR + BC [phase III (NCT02115282)], compared to exemestane / tamoxifen separately. [11]

2.3.4. Steroid sulfatase inhibitors

The primary enzyme that controls the transformation of sulfate-conjugated steroids into energy bureaucracy and non-conjugated estrogenic is steroid sulfatase. The steroid sulfatase enzyme's expression phase and sensitivity were shown to be considerably boosted in ER-wonderful BC. As a result, inhibiting steroid sulfatase is a viable strategy to minimise estrogenic steroids that can cause a BC. A recent phase ii study found that the combination of irosustat (a first-generation steroid sulfatase inhibitor) and aromatase inhibitor was well tolerated and resulted in scientific breakthroughs. Every other new dual-acting steroid sulfatase inhibitor (SR16157), which blocks steroid sulfatase immediately and releases the desired ER modulator, has been studied in the hormone-induced BC model. [12]

3. HER2+ BC

3.1. Current treatment regimens

A few molecular-focused advertisers were permitted to use HER2 + BC alone or in conjunction with common chemotherapy in HER2 + BC. They are: (i) trastuzumab (anti-HER2 monoclonal antibody); (ii) pertuzumab (anti-HER2 monoclonal antibody with a binding site different from HER2 than trastuzumab); (iii) ado-trastuzumab emtansine, an antibody-cytotoxic conjugate-like agent of trastuzumab associated with a small molecule of microtubule To see if they can benefit from HER2 anti-inflammatory medicines, BC patients are evaluated for HER2 genetic enhancement or protein dosage. The same old system of adjuvant treatment with a mix of chemotherapy and anti-HER2-based therapies is used early in HER2-superb BC. That goes for surgeries, radiation, and everything else. For the next 12 months, surgery, radiation, and all other HER2-based treatments are off limits. Depending on the biology of most malignancies, an endocrine adjuvant therapy may be used. The overall universal survival (OS) of patients with HER2 + superior BC increased from around 20 months to nearly 5 years with the debut of HER2 targeted therapeutic options 15 years ago. [13]

3.2. Novel healing procedures

The rise of primary and acquired trastuzumab resistance is severely limiting its therapeutic use in HER2+ BC. The development of targeted marketers and immunotherapies, as well as the elucidation of resistance mechanisms, have resulted in improved treatment outcomes (DESK 1) [14]

3.2.1. 1PI3K/AKT/mTOR inhibitors

With the help of divergent usage, a combination of PI3K/AKT/MTOR inhibitors comprising trastuzumab was tested to overcome trastuzumab resistance in lemons. When coupled with lapatinib, trastuzumab, or trastuzumab and paclitaxel, pan elegance PI3K inhibitors (buparlisib and pilaralisib) have shown good effectiveness and promising protection in patients with high HER2 + high BC. In patients with HER2 + superior BC, an AKT inhibitor (MK-2206) was found to have anticancer activity when combined with trastuzumab or trastuzumab with paclitaxel. In terms of the mTOR inhibitor, the combination of everolimus (mTOR inhibitor) with trastuzumab and vinorelbine has not significantly improved clinical outcomes in previously treated HER + BC patients. This combination, nevertheless, has become a spot to offer greater anti-cancer leisure time to patients than trastuzumab alone + also with hr. However, two recent mTOR inhibitors, ridaforolimus and sirolimus, as well as trastuzumab, have shown promise in HER2 + BC patients. [15]

3.3. Inhibitors targeting on HER-own family receptors

The anti-cancer impact of trastuzumab can be inhibited by enlarging the elements of its associate receptor compound [HER1 (EGFR), HER3, and OR HER4]. Furthermore, excessive exposure to HER2 / HER3 heterodimers has been linked to trastuzumab resistance, which is more likely than other heterodimers or homodimers formed by his own family. As a result, a comprehensive inhibition of his family's receptors could have a greater anticancer effect than only trastuzumab. [16]

3.3.1. Multi-concentrated on TKIS

After trastuzumab-based adjuvant therapy in HER2+ BC, neratinib, an irreversible TKI of HER1/HER2/HER4, has been shown to significantly improve 2-year invasive disorder-free survival. [17]

3.3.2. Monoclonal antibodies

Patritumab (anti-HER3 monoclonal antibody) inhibited the production of HER2/HER3 heterodimers in preclinical research, indicating that it has anticancer potential. It was found to have good efficacy and tolerability in patients with HER2+ advanced breast cancer. Margetuximab (HER2-targeted antibody) was well-tolerated, and it showed promise as a single-agent therapy in HER2+ advanced BC in a phase I trial. More clinical trials are being conducted to see if it can be used alone (NCT02492711) or in combination with pembrolizumab (NCT02689284).[18]

3.3.3. Antibody-drug conjugate (ADC)

Trastuzumab emtansine is an ADC that combines trastuzumab's HER2-concentrated on efficacy with a microtubule-inhibitory drug's cytotoxicity. It's approved as a second-line treatment for HER2+ BC that has relapsed or become resistant to trastuzumab/lapatinib.[19]

3.3.4. Farnesyl transferase inhibitors (FTI)

Lonafarnib, a particular FTI, suppresses RAS activity by farnesylation. Despite the fact that RAS mutations are uncommon in BC (less than 2%), the RAS protein and its downstream effectors are frequently activated as a result of upstream signalling molecules being overexpressed (e.g., HER2). Currently, a phase I trial shows that combining lonafarnib with trastuzumab and paclitaxel treatment improves anticancer activity in HER2+ advanced BC patients.[20]

3.3.5. Immunotherapy

Nelipepimut-s is a shorter peptide (HER2/NEU 369–377, KIFGSLAFL) from the extracellular region of HER2. It was studied as a vaccine to save you scientific resurgance in high-danger BC sufferers. The combo use of nelipepimut-s and trastuzumab in HER2+ early BC is now explored in a phase IIB trial (NCT02297698). Every other protein vaccine, recombinant HER2 protein (DHER2) changed into additionally observed to showcase immunogenicity to induce T-Mobile-mediated cytotoxicity in HER2+ early BC patients as an adjuvant therapy, in HER2+ advanced BC sufferers as a single agent and in HER2+ enhanced BC patients refractory to trastuzumab+ lapatinib.[21,22]

4. Triple Negative Breast Cancer

4.1. Modern remedy regimens

Most triple negative breast cancers are more aggressive and difficult to treat than HR+ and HER2+ breast cancers. Fashionable chemotherapy remains the mainstay of treatment for TNBC. TNBC is the BC subtype that has the best overall response to treatment (22 percent). However, their rates of recurrence and metastasis are lower than those with non-TNBC tumours. With standard cytotoxic marketers, the median OS for patients with metastatic TNBC is about 9–12 months. Chemotherapy [typically taxanes, anthracyclines, and platinum medicines] with or without bevacizumab [aRecombinant humanised monoclonal antibody against vascular endothelial growth factor (VEGF)] is the best authorised systemic remedy choice in advanced TNBC due to the lack of ER, PR, and HER2 expression. Given the unsatisfactory treatment outcomes with chemotherapy, further focused research is needed.[23]



Fig. 1:

Figure 1 investigative New drug for triple negative breast cancer (TNBC). Parp inhibitors are potent against mutated BRCA (BC) breast cancer. When BRCA activity is absent and the parp is blocked, cancer cells cannot repair DNA damage via homologous regeneration or base-excision correction and cell death activities. The antibody-drug unit, glembatumumab vedotin, may be effective in GPNMB-overexpressing BC by releasing cytotoxic drug into GPNMB that generates tumor cells, resulting in target cell death. Tyrosine kinase inhibitors against EGFR, VEGFR, and SRC have been investigated for TNBC treatment because these receptors sign up for the growth of cancer cells that have been overexpressed or discontinued on TNBC. The monoclonal antibody, pembrolizumab, may act on the PD-L1 expression by invading the immune system to kill cancer cells. Abbreviations: parp, poly (ADP-ribose) polymerase; GPNMB, glycoprotein NMB; AR, androgen receptor; DHT, dihydrotestosterone; PD-1, programmed death cell 1 receptor; PD-L1, ligand cell programmed death 1 receptor; EGFR, an epidermal growth factor receptor.[24]

The drug's characteristics and sensitivity are unique. To uniformly refine this therapeutic technique, clinical markers of drug-related biological reactions must be identified and classified.

4.1.1. Anti-Angiogenic Agent

TNBC is expected to have much higher intra-tumoral expression of VEGF, an essential angiogenic factor, than non-TNBC BC. Anti-VEGF monoclonal antibody

bevacizumab inhibits tumour neovasculature growth and prevents metastasis. The addition of bevacizumab to first-line chemotherapy (docetaxel) has been demonstrated to improve the response rate (placebo and docetaxel: 46% vs. bevacizumab and docetaxel: 64%) and median PFS in metastatic TNBC (phase III) (placebo). bevacizumab plus docetaxel: 81 months vs bevacizumab plus docetaxel: ten months) (HR, 0.67; p 0.001). Notably, the combining of bevacizumab and docetaxel had no effect on the system's overall safety profile.[25]

4.1.2. EGFRInhibitors

TNBC overemphasises the receptor component for epidermal growth. Efficacy of cetuximab (anti-EGFR monoclonal antibody) in conjunction with cisplatin in metastatic TNBC has been studied in a number of phase II trials. Even though a high-target response rate (ORR) was found (ORR = 20% cisplatin plus cetuximab vs. 10% cisplatin alone), cisplatin and cetuximab resulted in a longer median PFS (3.7 vs. 1.5 months) and median OS (12.9 vs. 9.4 months) when compared to cisplatin alone. A small number of TNBC patients who may respond to egfr inhibitors are now being sought. Lower alpha-crystalline b chain expression, improved PTEN expression, and a lack of KRAS expression inside plants might all be linked to the desired response.[26]

4.1.3. 3SRC inhibitors

TNBC has terminated / destroyed the SRC, a non-receptor signalling kinase that is downstream of various aspect receptors (EGFR, IGF-1R, PDGFR, and HGFR). When investigated as a single TNBC drug in a possible, open, phase II study (CA180059), dasatinib (more than one inhibitor of tyrosine kinases linked with SRC) had a dismal result. The goal response rate (ORR) was found to be quite efficient at 4.7 percent. PFS was 8.3 weeks on average. Adverse effects, dose discount, and more severe side effects are all linked to higher dosages (100 mg bid). However, when dasatinib was combined with cetuximab (anti-EGFR monoclonal antibody) and cisplatin in cell research, the TNBC cell type panel's interest in synergistic anticancer treatment shifted. A three-drug combination resulted in much more apoptosis and suppression of EGFR and MAPK phosphorylation than a single-drug combination. Dasatinib in my solution or combination therapy with dasatinib also affected the migration and invasion of numerous cancer cells in TNBC cell lines, becoming increasingly inhibited. As a result, clinical study into the use of dasatinib combinations in TNBC patients with co-overexpressed co-overexpressed tumours both egfr and C-SRC may be justified.[27]

4.1.4. Monoclonal antibodies

A three-drug combination caused much more apoptosis and suppression of EGFR and MAPK phosphorylation than a single-drug combination. In addition, dasatinib in my solution or combination treatment with dasatinib reduced the migration and invasion of various cancer cells in TNBC cell lines. As a result, clinical study into the use of dasatinib combinations in TNBC patients with co-overexpressed egfr and C-SRC tumours may be needed.[18]

4.2. Immunotherapies

Pembrolizumab is a human monoclonal antibody (IGG4-) that prevents 1 receptor from being lost (PD-1). It has been scientifically demonstrated to provide protection and effectiveness for people with high TNBC levels. PD-1 disables the immune system by inhibiting T cells, preventing the immune system from destroying a large number of cancer cells. Pembrolizumab's anticancer activity appears to be independent of PD-L1-related expression and everything, according to current phase II research. Patients with PD-L1 (PD-1-ligand)-enhanced TNBC have been chosen for examination in the IB phase. Pembrolizumab also exhibited long-term antitumor antagonism in individuals with metastatic TNBC who had been heavily pretreated.[28]

5. Conclusion

Within the previous decade, BC death rates have decreased due to the development of BC chemotherapy. In HR + BC, focusing on ER has proven to be one of the most effective treatments. The efficacy of biological therapies like the anti-HER2 monoclonal antibody has further underlined the potential and necessity of cell identification in the treatment of BC. TNBC metering, on the other hand, is still a severe disease with little treatment options. The molecular mechanisms that cause a distinct pharmacological response to BC have been better defined in recent years. This has prompted the creation of novel-targeted advertisements, such as PARP inhibitors, CDK4/6, PI3K/AKT/MTOR, a few kinases, or an antibody test, to treat various BC cell sub types.

6. Source of Funding

None.

7. Conflict of Interest

None.

References

1. Hosseini M, Hassannejad R, Khademolghorani SH, Tabatabaeian M, Mokarian F. Identification of Patterns of Breast Cancer Metastasis among Women Referred to Isfahan Seyedoshohada Center, Iran, between 1999 and 2009 by Association Rules and Ordinal Logistic Regression. *Sci Res J Health Syst Res*. 2012;7(6):746–62.
2. Filhart MD, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, et al. Classification of breast cancer using genetic algorithms

and tissue microarrays. *Clin Cancer Res*. 2006;12(21):6459–68. doi:10.1158/1078-0432.CCR-06-1383.
3. Francis G, Beadle G, Thomas S, Mengersen K, Stein S. Evaluation of oestrogen and progesterone receptor status in Her-2 positive breast carcinomas and correlation with outcome. *Pathology*. 2006;38(5):391–8. doi:10.1080/00313020600922488.
4. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. *J Natl Cancer Inst*. 2002;94(11):855–7. doi:10.1093/jnci/94.11.855.
5. Peto R, Davies C, Godwin J. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet*. 2012;379(9814):61625–30.
6. Mackey JR, Martin M, Pienkowski T. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. *Lancet Oncol*. 2013;14(1):72–80. doi:10.1016/S1470-2045(12)70525-9.
7. Deo SV, Bhutani M, Shukla NK. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). *J Surg Oncol*. 2003;84(4):192–7. doi:10.1002/jso.10323.
8. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. *Curr Opin Pharmacol*. 2015;23:98–107. doi:10.1016/j.coph.2015.05.016.
9. Choueiri TK. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(1):917–27.
10. Zhang Y, Zhang J, Xu K, Sun XZ, Xu J. PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. *Hepatogastroenterology*. 2013;60(127):1766–72.
11. Porter NJ, Mahendran A, Breslow R. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. *Proc Natl Acad Sci*. 2017;114(51):13459–64. doi:10.1073/pnas.1718823114.
12. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011;365:1273–83.
13. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. *Ann Oncol*. 2001;12(1):9–13. doi:10.1093/annonc/12.suppl_1.s9.
14. Jorgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. *J Cancer*. 2012;3(1):137–81.
15. Cunningham D, Allum WH, Stenning SP, Thompson JN, De Velde CJV, Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med*. 2006;355(1):11–20.
16. Zuo WJ, Jiang YZ, Wang YJ. Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. *Clin Cancer Res*. 2016;22(19):4859–69. doi:10.1158/1078-0432.CCR-15-3036.
17. Wong DJ, Hurvitz SA. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. *Ann Transl Med*. 2014;2(12):122. doi:10.3978/j.issn.2305-5839.2014.08.13.
18. Sorlie T, Tibshirani R, Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci USA*. 2003;100(14):8418–23.
19. Carey LA, Dees EC, Sawyer L. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res*. 2007;13(8):2329–34. doi:10.1158/1078-0432.CCR-06-1109.
20. Cobleigh MA, Tabesh B, Bitterman P. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. *Clin Cancer Res*. 2005;11(24):8623–31. doi:10.1158/1078-0432.CCR-05-0735.
21. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. *Am J Epidemiol*. 1988;128(3):467–77. doi:10.1093/oxfordjournals.aje.a114995.
22. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. *Am J Epidemiol*. 1987;125(5):769–79. doi:10.1093/oxfordjournals.aje.a114594.
23. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. *Proc Natl Acad Sci U S A*. 2004;101(52):18123–8. doi:10.1073/pnas.0408273101.
24. Ukwenya AY, Yusufu LMD, Nmadu PT, Garba ES, Ahmed A. Delayed treatment of symptomatic breast cancer: the experience from Kaduna. *South Afr J Surg*. 2008;46(4):106–111.
25. Saghir NS, Adebamowo CA, Anderson BO. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. *Breast*. 2011;20(2):3–11.
26. Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?". *Cancer*. 2005;103(8):1540–50. doi:10.1002/cncr.20978.
27. Clifton KH, Sridharan BN, Douple EB. Mammary carcinogenesis-enhancing effect of adrenalectomy in irradiated rats with pituitary tumor MtT-F4. *J Natl Cancer Inst*. 1975;55:485–487.
28. Boice JD, Preston D, Davis FG, Monson RR. Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. *Radiat Res*. 1991;125(2):215–22.

Author biography

A.G. Nerkar, Professor

Cite this article: Nerkar AG. Recent advances in treatment of breast cancers. *Curr Trends Pharm Pharm Chem* 2022;4(2):67-74.